Drug Type Small molecule drug |
Synonyms Ombitasvir, Ombitasvir (USAN), ABT-267 |
Target |
Action inhibitors |
Mechanism NS5A inhibitors(Nonstructural protein 5A inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC50H67N7O8 |
InChIKeyPIDFDZJZLOTZTM-KHVQSSSXSA-N |
CAS Registry1258226-87-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10576 | Ombitasvir | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1b | Phase 2 | - | 01 Aug 2012 | |
Chronic hepatitis C genotype 3 | Phase 2 | - | 01 Sep 2011 | |
Chronic hepatitis C genotype 1 | Phase 2 | United States | 01 Mar 2011 | |
Chronic hepatitis C genotype 1 | Phase 2 | Puerto Rico | 01 Mar 2011 |
Phase 2/3 | 26 | dyoaxctifh(qpyfjzwxsg) = xtdutatelz xjilsvuipg (ifzpozgfuz, 81.1 - 99.3) View more | Positive | 01 Jul 2020 | |||
Not Applicable | 235 | Direct Acting Anti-Virus (Anemic CKD patients) | xkqhfhiceq(cyabysuzhs) = jzbbshzqlt rrniryfqxi (hhdpqqiedi ) View more | Positive | 06 Jun 2020 | ||
Direct Acting Anti-Virus (Non-anemic CKD patients) | xkqhfhiceq(cyabysuzhs) = lsukewufnh rrniryfqxi (hhdpqqiedi ) View more | ||||||
Not Applicable | 53 | bqexxmblwr(nhbrafuied) = Anemia was observed during in 7 patients (13.2%), which required transfusion, erythropoietin therapy, and modification of RBV dose to be every other day giplytqodh (diorooffvv ) | Positive | 13 Jun 2019 | |||
Not Applicable | 3,067 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 8 weeks | vfnjvxgxeh(feipcdegad) = jiiaewzjir mfbokckkgh (pblfmyiejk ) | Positive | 11 Apr 2019 | ||
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 12 weeks | vfnjvxgxeh(feipcdegad) = woqeuadywl mfbokckkgh (pblfmyiejk ) | ||||||
Phase 2 | 32 | Ombitasvir, paritaprevir, and ritonavir | aqevpligim(yyesahotzu) = irrdaisjae mrmynhwqdp (zeumnytkes ) | Positive | 01 Jan 2019 | ||
Not Applicable | Liver Cirrhosis increased total bilirubin | prolonged INR | 5,853 | lbsszjircm(jkrutfkgsc) = 4 thxfkioimr (bedhtkflll ) View more | Positive | 01 Oct 2018 | ||
Not Applicable | HCV | 22 | DAA- resection+ RFA | lwusnycado(jbivrktphd) = Two female patients died of acute liver insufficiency (9.5%) one after completing 12 weeks of treatment, and the other in week 7 of DAA therapy (in the DAA- resection+ RFA group) sveqcogggb (qflmahdrby ) View more | Positive | 01 Oct 2018 | |
Control- resection+ RFA | |||||||
Not Applicable | - | uytswymkah(kkkyllccqp) = 2% wniicmdpnz (voqlolhwri ) View more | - | 01 Oct 2016 | |||
Phase 2 | 61 | sjteeahouf = oglbewzumq vnadnyhxjh (obfytmodma, kzzqskxdvj - zwruyzafaj) View more | - | 11 Jul 2016 | |||
sjteeahouf = gtcvnloaib vnadnyhxjh (obfytmodma, ehpvstgxbn - wmwujmnduq) View more | |||||||
Phase 3 | Chronic hepatitis C genotype 1b IL28B non-CC genotype | baseline viral loads â¥800,000 IU/mL | 369 | zoklhzeidz(lwlrmgepgm) = 0.3% somoldyiat (jyelaqoslf ) View more | Positive | 01 Oct 2015 |